[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minia University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":661},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,85,0,25,[9,43,84,118,150,194,221,242,270,293,314,342,373,393,410,430,456,475,502,519,540,560,581,611,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652920","evaluation-of-the-effect-of-different-irrigation-activation-methods-during-endodontic-retreatment-100652920",false,"NCT07779148","Evaluation of the Effect of Different Irrigation Activation Methods During Endodontic Retreatment","Evaluation of the Effect of Different Irrigation Activation Methods During Endodontic Retreatment on Postoperative Pain and Periapical Healing in Single-Rooted Teeth: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with mature teeth.\n* Patients with failed previous Endo treatment related by periapical periodontitis\n* Single Rooted with single root canal.\n* Patients should be free from any systemic disease that may affect predictable outcome.\n* Patients who agree to the consent and will commit to follow-up period\n\nExclusion Criteria:\n\n* Patients with immature roots.\n* Patients with any systemic disease that may affect normal healing.\n* Patients with swelling.\n* Pregnant females.\n* Patients who could\u002Fwould not participate in follow-up.\n* Patients with old age.\n* Teeth with periodontal involvement.\n* Teeth with vertical root fractures.\n* Non-restorable teeth",true,"ALL","13 Years","60 Years",{"count":22,"type":23},34,"ESTIMATED","INTERVENTIONAL",[26],"NA","The persistent and secondary intraradicular infections are the primary causes of post-treatment disease following endodontic treatment of any tooth. When conventional root canal treatment fails, endodontic retreatment is often the preferred option, as it represents one of the most conservative approaches.\n\nEndodontic retreatment involves removing old root canal filling material followed by cleaning, shaping, and refilling the canals. It may be associated with postoperative pain due to periapical tissue irritation and apical extrusion of debris during instrumentation.",[29],"Endodontic Inflammation","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-08-01",{"date":38,"type":23},"2027-08-10",{"name":40,"class":41},"Minia University","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100648846","ct-volumetry-and-hepatic-vascular-deformation-mapping-to-predict-post-hepatectomy-liver-failure-100648846","NCT07727759","CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure","Beyond Size - Integrating CT Volumetry With Hepatic Vascular Deformation Mapping to Anticipate Post-Resection Congestion and Liver Failure","BEYOND-SIZE","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo major hepatic resection, defined as the removal of three or more Couinaud segments, at a participating center\n* Availability of a preoperative multiphasic contrast-enhanced CT of the liver of quality sufficient for central core-laboratory analysis\n* Willing and able to complete postoperative clinical and laboratory follow-up for at least 30 days\n* Written informed consent\n\nExclusion Criteria:\n\n* Minor hepatic resection (fewer than three Couinaud segments)\n* Significant pre-existing vascular anomaly or vascular pathology (for example, portal vein thrombosis)\n* Emergency hepatic resection for trauma\n* Preoperative imaging that fails central quality control\n* Incomplete follow-up data","18 Years",{"count":53,"type":23},1070,"OBSERVATIONAL","Removing a large part of the liver (major hepatectomy) can cure primary and secondary liver cancers, but it carries the risk of post-hepatectomy liver failure (PHLF), a serious complication in which the liver left behind - the future liver remnant (FLR) - cannot meet the body's metabolic needs. PHLF occurs after roughly 5% to 15% of major hepatectomies and is the leading cause of postoperative death.\n\nBefore surgery, surgeons routinely use CT scans to measure how much liver will remain (CT volumetry). Volume alone does not tell the whole story. After a large resection the remaining liver can rotate and shift into the empty space left behind, kinking or compressing the veins that drain it. The resulting congestion can make an apparently adequate remnant fail.\n\nThis prospective, multicenter, observational cohort study tests whether adding two elements to standard CT volumetry improves the preoperative prediction of liver failure:\n\n1. Hepatic vascular deformation mapping (VDM), a three-dimensional image-analysis technique that quantifies the geometry and displacement of the hepatic veins and the portal vein; and\n2. A set of simple, reproducible measurements that any radiologist can make on a standard CT scan (hepatic vein diameters, congestion index, spleen volume, liver attenuation, and the distances from the veins to the planned resection plane).\n\nConsecutive adults undergoing major hepatic resection (three or more Couinaud segments) at several tertiary hepatobiliary centers will be enrolled. The preoperative CT scans already performed as part of routine care are analyzed centrally by a core imaging laboratory. There is no additional imaging, no extra hospital visit, and no study-specific intervention: every patient receives standard surgical care. Participants are followed for at least 30 days after surgery to record liver failure (International Study Group of Liver Surgery criteria, operationalized by the \"50-50\" rule on postoperative day 5) and radiologic evidence of hepatic congestion.\n\nThree nested prediction models are compared - volumetry alone; volumetry plus VDM; and volumetry plus VDM plus the simple radiology parameters - and the best-performing model is converted into a practical risk score. Because the study runs across several centers, the model can be validated by leaving one center out at a time, which gives an honest estimate of how well it would perform at a new hospital. The goal is a generalizable, easy-to-use tool that tells surgeons, before the operation, which patients are genuinely at risk of post-hepatectomy liver failure.",[57,58,59,60,61,62,63],"Post-Hepatectomy Liver Failure","Liver Failure","Liver Neoplasms","Carcinoma, Hepatocellular","Liver Metastases","Postoperative Complications","Hepatic Congestion",[65,66,67,68,69,70,71,72,73,74,75],"post-hepatectomy liver failure","CT volumetry","future liver remnant","vascular deformation mapping","hepatic venous congestion","major hepatectomy","clinical prediction model","ISGLS criteria","congestion index","hepatobiliary surgery","risk stratification","2026-08-17",{"date":31,"type":34},{"date":79,"type":34},"2026-08-15",{"date":81,"type":23},"2028-07-31",{"name":40,"class":41},3,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100652627","a-trial-to-evaluate-two-ectropion-preventive-measures-using-the-subciliary-approach-in-orbital-fracture-surgery-100652627","NCT07775417","A Trial to Evaluate Two Ectropion Preventive Measures Using the Subciliary Approach in Orbital Fracture Surgery.","A Comparative Clinical Trial Evaluating Preventive Techniques for Postoperative Ectropion Following the Subciliary Approach in Orbital Trauma.","PREVENTECT","Inclusion Criteria:\n\n* Systemically healthy patients aged 18 years or older, with no history of chronic or uncontrolled systemic diseases.\n* Patients with primary orbital trauma requiring surgical treatment through a standardized subciliary approach, presenting with orbital floor fractures with or without associated lateral orbital rim fractures involving the lateral canthal tendon region, and without associated zygomaticomaxillary complex (ZMC) fractures.\n\nExclusion Criteria:\n\n* Secondary orbital trauma (revision cases or patients with previous orbital trauma).\n* Previous lower eyelid surgery.\n* Pre-existing eyelid malposition (ectropion or entropion) or other pre-existing lower eyelid or lateral canthal abnormalities.\n* Uncontrolled systemic conditions that may affect wound healing, eyelid integrity, or lower eyelid laxity, including uncontrolled diabetes mellitus, immunocompromised status, chronic corticosteroid therapy, or collagen vascular diseases.\n* Previous radiotherapy to the orbital or facial region.",{"count":93,"type":23},30,[26],"The goal of this clinical trial is to investigate whether preventive surgical techniques can reduce the incidence of lower eyelid ectropion after the subciliary approach in adult patients undergoing surgery for orbital fractures.\n\nThe main questions it aims to answer are:\n\nDo lateral canthopexy or orbicularis oculi suspension reduce the incidence of postoperative ectropion? Which preventive technique provides better postoperative lower eyelid outcomes?\n\nResearchers will compare three groups: subciliary approach alone, subciliary approach with lateral canthopexy, and subciliary approach with orbicularis oculi suspension to investigate which approach is most effective in preventing postoperative ectropion.\n\nParticipants will undergo surgical treatment according to their assigned group and will attend scheduled postoperative follow-up visits for clinical evaluation of lower eyelid position and surgical outcomes.",[97,98],"Orbital Fractures","Orbital Floor Fractures",[97,100,101,102,103,104,105,106,107,108],"Orbital Floor Fracture","Subciliary Approach","Ectropion","Lateral Canthopexy","Orbicularis Oculi Suspension","Lower Eyelid Malposition","Orbital Reconstruction","Oral and Maxillofacial Surgery","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-08-16",{"date":112,"type":34},"2026-08-20",{"date":114,"type":23},"2026-09-01",{"date":116,"type":23},"2027-11-30",{"name":40,"class":41},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":127,"conditions":128,"keywords":135,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":42},"100648811","risk-factors-for-mesh-infection-after-abdominal-wall-reconstruction-100648811","NCT07725718","Risk Factors for Mesh Infection After Abdominal Wall Reconstruction","Risk Factors for Mesh-Related Infection in Abdominal Wall Reconstruction: A Single-Centre Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Undergoing elective or urgent abdominal wall reconstruction with implantation of synthetic, biosynthetic or biological mesh for a ventral, incisional, parastomal or complex abdominal wall defect.\n* Able and willing to provide written informed consent and to attend scheduled follow-up.\n\nExclusion Criteria:\n\n* Suture-only repair without mesh.\n* Inguinal or femoral (groin) hernia repair.\n* Active systemic sepsis or established intra-abdominal mesh infection at the time of index surgery.\n* Mesh placed solely for a non-reconstructive indication (e.g. temporary abdominal closure or planned re-look without definitive reconstruction).\n* Estimated life expectancy \\\u003C 12 months or inability to complete the minimum follow-up.\n* Patient declines participation.",{"count":126,"type":23},420,"Abdominal wall reconstruction (AWR) with mesh is the standard repair for ventral, incisional, parastomal and complex abdominal wall defects, but mesh-related infection remains one of its most serious complications - prolonging hospital stay, often requiring reoperation or removal of the mesh, and increasing the risk of hernia recurrence. Reported infection rates vary widely, and the independent contribution of individual risk factors remains uncertain, in large part because much of the existing evidence comes from retrospective series with inconsistent outcome definitions.\n\nThis single-centre, prospective observational cohort study will enrol consecutive adults undergoing elective or urgent AWR with synthetic, biosynthetic or biological mesh at a tertiary referral hernia unit. Participants will be followed for 12 months on a fixed schedule (7-10 days, 30 days, 90 days, 6 months and 12 months). Using internationally accepted, prespecified definitions of mesh infection and surgical site occurrence, the study will collect up to 18 candidate patient, defect, operative and perioperative risk factors and analyse them by multivariable logistic regression to identify the independent predictors of mesh-related infection within 90 days of surgery.\n\nSecondary aims are to describe the incidence, timing, microbiology and management (salvage versus explantation) of mesh infection; to report surgical site occurrences and reoperation; and to derive an exploratory risk-stratification model. The findings are intended to support preoperative risk assessment, targeted patient optimisation, informed mesh and technique selection, and shared decision-making. The study is designed and reported in accordance with the STROBE statement.",[129,130,131,132,133,134],"Incisional Hernia","Ventral Hernia","Parastomal Hernia","Abdominal Wall Defect","Surgical Wound Infection","Prosthesis-Related Infections (Mesh Infection)",[136,137,138,139,140,141,142,143,144],"Mesh infection","Abdominal wall reconstruction","Surgical site occurrence (SSO)","SSO requiring procedural intervention (SSOPI)","Risk factors","Prosthetic mesh","Component separation \u002F transversus abdominis release","Hernia recurrence","Surgical site infection",{"date":31,"type":34},{"date":79,"type":34},{"date":148,"type":23},"2028-08-15",{"name":40,"class":41},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":161,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":193,"locationsCount":42},"100648262","hernia-sac-flap-coverage-of-mesh-in-bony-edged-ventral-hernia-repair-100648262","NCT07720154","Hernia Sac Flap Coverage of Mesh in Bony-Edged Ventral Hernia Repair","Sac-Flap Peritonealization of Mesh in Bony-Edged Ventral Hernias: A Randomized Controlled Trial","PERI-SAC","Inclusion Criteria:\n\n* Age 18 years or older.\n* Elective open repair planned for a complex ventral hernia (primary or incisional) in which at least one margin of the fascial defect is formed by bone - that is, a subxiphoid or costal-margin, suprapubic, or iliac or lumbar location - confirmed on cross-sectional imaging (CT or MRI) and at operation.\n* A hernial sac of sufficient quality and surface area to raise a pedicled flap adequate to cover the planned mesh, as judged at operation.\n* Planned retromuscular (sublay) synthetic mesh repair, with or without posterior component separation (transversus abdominis release).\n* Able to give written informed consent and to attend scheduled follow-up for 12 months.\n\nExclusion Criteria:\n\n* Emergency or urgent operation (incarceration with strangulation, obstruction, or perforation).\n* Active intra-abdominal infection, or a contaminated or dirty operative field (CDC wound class III-IV) at the time of randomization.\n* Planned use of biologic or composite intraperitoneal mesh, or a bridged (non-fascial-closure) repair as the primary plan.\n* Hernial sac absent, destroyed, densely scarred, or too small to raise a viable covering flap.\n* Concurrent bowel resection or stoma creation expected to alter the wound-contamination class.\n* ASA physical status V.\n* Life expectancy less than 12 months, or active malignancy under treatment with anticipated short survival.\n* Pregnancy.\n* Inability or unwillingness to provide informed consent or to comply with follow-up","75 Years",{"count":160,"type":23},180,[26],"This trial asks whether covering the inner, bowel-facing surface of a hernia mesh with a flap of the patient's own hernia sac improves healing after repair of a complex ventral (abdominal wall) hernia in which one edge of the defect is bone - for example hernias next to the breastbone and ribs, above the pubic bone, or at the iliac crest.\n\nIn these \"bony-edged\" hernias the mesh is both hardest to fix and hardest to cover. There is no fascia on the bony side for the surgeon to stitch the mesh to, and the lining layer of the abdomen cannot be closed underneath the mesh because the plane that carries it stops at the bone. The mesh may therefore be left in contact with the bowel, which can lead to dense adhesions, mesh erosion, chronic pain and, rarely, a fistula.\n\nNormally the hernia sac - the thin membrane that lines the hernia - is cut away and discarded. In this trial the surgeon instead preserves it as a living, blood-supplied flap, rotates it underneath the mesh, and stitches it in place as a new lining layer that separates the mesh from the bowel and covers the bony edge. The technique uses only the patient's own tissue: no extra mesh, no donor site and no added cost.\n\nOne hundred and eighty adults undergoing planned (non-emergency) open repair of a bony-edged complex ventral hernia will be randomly assigned in equal numbers to one of two groups: standard retromuscular (sublay) mesh repair with the added sac flap (90 participants), or standard retromuscular mesh repair alone, with the sac handled in the conventional way (90 participants). Every other step of the operation is the same in both groups.\n\nThe main question is whether the sac flap reduces the number of participants who develop any wound or mesh problem in the first 30 days after surgery. This is measured as a composite called a surgical site occurrence, which includes wound infection, seroma, haematoma, skin or soft-tissue death, wound breakdown, mesh exposure and fistula. The trial also compares complications needing a drainage or operative procedure, hernia recurrence at 12 months, overall complication severity, operating time, blood loss, hospital stay, readmission, reoperation, pain, quality of life and death.\n\nParticipants, ward and clinic staff, the doctors who assess the wounds, the radiologist who reads the follow-up scans and the trial statistician will not know which operation was performed; only the operating surgeon will. The group assignment is revealed only during the operation, after the surgeon has confirmed that the defect truly has a bony edge and that the sac is suitable for a flap. Participants are followed for 12 months.",[129,164,165,166,167,62,130],"Abdominal Hernia","Complex Ventral Hernia","Surgical Site Infection","Seroma",[169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189],"ventral hernia","incisional hernia","complex abdominal wall reconstruction","bony-edged hernia","subxiphoid hernia","suprapubic hernia","lumbar hernia","iliac crest hernia","hernial sac","sac flap","peritonealization","neo-peritoneum","autologous tissue coverage","retromuscular mesh","sublay mesh repair","transversus abdominis release","posterior component separation","surgical site occurrence","mesh-visceral interface","mesh erosion","hernia recurrence",{"date":31,"type":34},{"date":79,"type":34},{"date":148,"type":23},{"name":40,"class":41},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":158,"enrollmentInfo":201,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":42},"100625855","postoperative-hypocalcemia-after-thyroidectomy-100625855","NCT07428057","Postoperative Hypocalcemia After Thyroidectomy","A Ten-Year Cohort Study of Clinical and Surgical Predictors for Hypocalcemia Post-Thyroidectomy","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at time of surgery\n* Underwent thyroidectomy at Minia University Hospital\n* Availability of medical records with complete surgical and postoperative data\n* Documented serum calcium levels measured postoperatively\n* Minimum follow-up of 6 months postoperatively or documented outcome status\n\nExclusion Criteria:\n\n* Age less than 18 years at time of surgery\n* Preoperative hypocalcemia (serum calcium \\\u003C8.0 mg\u002FdL or ionized calcium \\\u003C1.0 mmol\u002FL)\n* Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)\n* Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)\n* Concurrent planned parathyroidectomy\n* History of neck irradiation\n* Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)\n* Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data\n* Patients lost to follow-up before 6-month endpoint without documented outcome status",{"count":202,"type":23},600,"This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.",[205,206,207,208,62],"Thyroid Nodule","Thyroid Dysfunction","Hypocalcemia","Thyroid Cancer",[210,211,212,213,214],"Thyroidectomy","Postoperative hypocalcemia","Hypoparathyroidism","Parathyroid gland injury","Total thyroidectomy",{"date":31,"type":34},{"date":217,"type":34},"2026-03-04",{"date":219,"type":23},"2027-01-01",{"name":40,"class":41},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":42},"100651995","influence-of-sealer-composition-on-post-endodontic-pain-100651995","NCT07767084","Influence of Sealer Composition on Post-Endodontic Pain","Influence of Sealer Composition on Post-Endodontic Pain: A Prospective Comparative Analysis of Three Root Canal Sealers","Inclusion Criteria:\n\n* Patients requiring primary root canal treatment.\n* Patients with acute irreversible pulpitis.\n* Patients in good general health\n\nExclusion Criteria:\n\n* Patients with systemic diseases affecting pain perception or healing.\n* Patients who had taken analgesics or antibiotics within 12-24 hours prior to treatment.\n* Pregnant or lactating women.\n* Previously treated teeth or teeth with root resorption, fractures, or severe periodontal disease","45 Years",{"count":230,"type":23},66,[26],"Postoperative pain (PP) is one of the most common and clinically significant complications following endodontic therapy, occurring shortly after treatment and potentially lasting from a few hours to several days, thereby compromising the patient's quality of life.\n\nThe incidence of PP varies widely in the literature, ranging from 1.7% to 70%, with some studies reporting values up to 80% within the first 24 hours, gradually decreasing over a week.",[234],"Post Endodontic Pain","2026-08-11",{"date":76,"type":34},{"date":238,"type":34},"2026-04-14",{"date":240,"type":23},"2027-04-14",{"name":40,"class":41},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":20,"enrollmentInfo":250,"targetDuration":4,"studyType":24,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":42},"100651468","comparison-between-socket-shield-and-conventional-techniques-in-immediate-implant-placement-100651468","NCT07761442","Comparison Between Socket Shield and Conventional Techniques in Immediate Implant Placement.","Comparative Study Between Using Socket Shield And Conventional Techniques In Immediate Implant Placement (A Randomized Clinical Trial)","Inclusion Criteria:\n\n* Patients aged between 20 and 60 years of both genders\n* All participants should be systemically healthy, as assessed using the dental modification of the Cornell Medical Index.\n* Gingival and periodontal health to be confirmed according to the criteria outlined in the new classification system proposed by Caton et al. (2018).\n* Presence of non-restorable teeth due to trauma, complicated crowns or root fractures.\n* Presence of extensive destructive caries making the tooth unsalvageable, particularly in esthetic zones.\n* Clinical indication for immediate implant placement, especially in cases where minimizing post-extraction bone resorption and soft tissue collapse is critical.\n* Availability of adequate interocclusal space to accommodate the necessary prosthetic components without occlusal interference.\n\nExclusion Criteria:\n\n(for socket-shield technique)\n\n* Pregnant female.\n* Patients with parafunctional habits (e.g., bruxism, clenching).\n* Smokers.\n* Teeth with clinical mobility.\n* Teeth with root fractures extending below the alveolar bone level.\n* Periodontal ligament space widening.\n* Signs of internal or external root resorption.\n* Current or previous periodontal disease","20 Years",{"count":251,"type":23},16,[26],"The goal of this randomized clinical trial is to compare whether immediate implant placement using the socket-shield technique can better preserve bone density, bone level, and peri-implant tissue health compared to conventional immediate implant placement in patients requiring tooth extraction in the maxillary esthetic zone.\n\nThis study is conducted in systemically healthy adult patients aged 20-60 years who have non-restorable maxillary anterior teeth indicated for immediate implant placement.\n\nThe main questions this study aims to answer are:\n\nDoes the socket-shield technique result in better peri-implant bone density and bone level preservation compared to the conventional immediate implant technique?\n\nDoes the socket-shield technique lead to improved clinical peri-implant parameters, including probing depth, bleeding on probing, keratinized tissue width, and soft tissue thickness?\n\nparticipants will be divided into two groups: (both groups will receive immediate implant placement of a tooth requiring extraction in the maxillary esthetic zone.) First group: will recieve immediate implant using conventional technique. second group: will recieve immediate implant using socket shield technique.\n\nParticipants will:\n\n* Undergo clinical and radiographic examinations, including cone beam computed tomography (CBCT).\n* Receive immediate implant placement using either the conventional technique or the socket-shield technique.\n* Be followed up clinically and radiographically for 9 months to assess bone and soft tissue healing.\n* Attend regular postoperative and follow-up visits for evaluation of implant stability and peri-implant tissue health.",[255,256,257,258,259,260,261],"Bone Density","Bone Level","Peri-Implant Tissues","Socket Shield Technique Implant Placement","Immediate Implant Placement","Root Submergence Technique","Single Tooth Lost","2026-08-10",{"date":264,"type":34},"2026-08-12",{"date":266,"type":34},"2025-10-20",{"date":268,"type":23},"2026-11",{"name":40,"class":41},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":158,"enrollmentInfo":278,"targetDuration":280,"studyType":54,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":42},"100597516","prevalence-and-predictors-of-incidental-thyroid-carcinoma-in-patients-with-graves-disease-undergoing-thyroidectomy-100597516","NCT07059507","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.","GD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Confirmed diagnosis of Graves' disease based on clinical features (e.g., diffuse goiter, ophthalmopathy if present) and biochemical evidence (suppressed TSH, elevated free T4 and\u002For T3) and\u002For positive TSH receptor antibody (TRAb) test.\n* Indication for total thyroidectomy for Graves' disease, based on established guidelines:\n\nRelapse or persistence of hyperthyroidism after a course of antithyroid drugs (ATDs).\n\nIntolerance or adverse reaction to ATDs. Patient preference for surgery over radioactive iodine (RAI) or long-term ATDs. Presence of a large goiter causing compressive symptoms. Coexisting suspicious thyroid nodule(s) on preoperative evaluation. Moderate to severe active Graves' ophthalmopathy where RAI is relatively contraindicated.\n\n* Patient is scheduled for total thyroidectomy (near-total or subtotal thyroidectomy patients will be excluded).\n* Ability and willingness to provide written informed consent.\n* Ability to understand study procedures and requirements.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Previous thyroid surgery.\n* Previous neck irradiation.\n* Preoperative diagnosis of thyroid malignancy confirmed by fine-needle aspiration (FNA) cytology (Bethesda V or VI) , the focus is on incidental carcinoma.\n* Inability to provide informed consent (e.g., due to cognitive impairment).\n* Patients undergoing thyroidectomy primarily for reasons other than Graves' disease (e.g., primary indication is large non-toxic MNG).\n* Patients undergoing less than total thyroidectomy (e.g., lobectomy, subtotal thyroidectomy).",{"count":279,"type":23},280,"1 Month","The prevalence of incidental thyroid cancer (ITC) in Graves' Disease (GD) patients undergoing thyroidectomy appears higher than historically believed, potentially exceeding 10% in large contemporary series, although significant variability exists. The presence of nodules is a strong predictor, while the roles of age, sex, and BMI require clarification. Most ITCs are papillary thyroid microcarcinoma(PTMCs) with generally favorable prognoses, but concerns about aggressiveness persist.\n\nThe purpose of the present study is to accurately evaluate the prevalence of incidental thyroid carcinoma (ITC), including microcarcinomas, in a prospectively enrolled cohort of patients undergoing total thyroidectomy for Graves' disease, utilizing standardized pathological examination protocols and secondary outcomes including predictors and histopathological characteristics.",[208,283],"Graves Disease",[285],"Incidental thyroid cancer","2026-08-08",{"date":235,"type":34},{"date":289,"type":34},"2025-07-15",{"date":291,"type":23},"2027-01-15",{"name":40,"class":41},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":299,"minAge":51,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":24,"phases":303,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":42},"100579417","early-phase-1-comparison-of-nebulized-neostigmineatropine-versus-lignocaine-in-treating-acute-post-dural-puncture-headache-following-subarachnoid-block-in-parturient-undergoing-elective-cesarean-section-a-randomized-clinical-trial-100579417","NCT06824025","Comparison of Nebulized Neostigmine\u002FAtropine Versus Lignocaine in Treating Acute Post-dural Puncture Headache Following Subarachnoid Block in Parturient Undergoing Elective Cesarean Section. A Randomized, Clinical Trial.","Inclusion Criteria:\n\n* 18-35 years old parturient with post partum headache after elective CS under spinal anesthesia with visual analog score (VAS) ≥ 4 \\[14\\] and Lybecker classification score ≥ 2\n\nExclusion Criteria:\n\n* Pregnancy induced hypertension\n* Emergency C.S\n* Asthmatic candidates\n* Previous history of migraine or trigeminal neuralgia\n* History of bronchial asthma\n* Post partum hemorrhage\n* Need for GA , failed spinal anesthesia\n* Patient refusal","FEMALE","35 Years",{"count":302,"type":23},111,[304],"EARLY_PHASE1","Post-dural puncture headache (PDPH) is a common and debilitating complication of spinal anesthesia in pregnant patients undergoing cesarean sections, with an incidence ranging from 0.5% to 2% (1). The International Headache Society (IHS) defines PDPH as a headache occurring within 4 days of a lumbar puncture, caused by cerebrospinal fluid (CSF) leakage through the dural puncture (2). Although the exact cause of PDPH is not fully understood, it is thought to occur due to cerebrospinal fluid loss through dural tears, which leads to tension on pain-sensitive intracranial structures and reflex, uncontrolled cerebral vasodilation leading to severe agonizing tension headache (3). Treatment options include proper hydration, maintaining a supine position, caffeine, paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs). Many adjuvants have been questioned for their therapeutic effectiveness in enhancing conservative medical treatments, with conflicting results (4). For example, sumatriptan, theophylline and dexmedetomidine have been extensively studied. Neostigmine has emerged as a promising pharmacological adjuvant for conservative management. Neostigmine increases the serum level of acetylcholine via inhibition of cholinesterase (5). This action mediates cerebral vasoconstriction via nicotinic receptors, thus antagonizing the unopposed vasodilatation occurred due to dural tear. Lidocaine, on the other hand, can mediate sphenopalatine ganglion block which is responsible for pain signals transmission from the face (6).",[307],"Post-Dural Puncture Headache",{"date":264,"type":34},{"date":310,"type":34},"2025-02-20",{"date":312,"type":23},"2027-01-05",{"name":40,"class":41},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":24,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":42},"100650665","assessing-the-role-of-proton-pump-inhibitors-in-reducing-aspiration-incidence-in-pediatric-laryngomalacia-cases-100650665","NCT07750379","Assessing the Role of Proton Pump Inhibitors in Reducing Aspiration Incidence in Pediatric Laryngomalacia Cases","Inclusion Criteria:\n\n1. Children diagnosed with laryngomalacia by laryngoscopic examination with a history of recurrent choking attacks or aspiration symptoms.\n2. Children aged from 6 months to 5 years.\n\nExclusion Criteria:\n\n1. Children with any neurological impairment.\n2. Children with other congenital anomalies.\n3. Children with other causes of respiratory distress","6 Months","5 Years",{"count":323,"type":23},60,[26],"Laryngomalacia is the most common congenital laryngeal anomaly in children and is frequently associated with aspiration. This randomized controlled study aims to assess the role of proton pump inhibitor (PPI) therapy in reducing the incidence of aspiration in pediatric patients with laryngomalacia. Eligible participants will be randomly assigned to either a PPI treatment group or a control group. Clinical and swallowing assessments will be performed to compare aspiration incidence and swallowing outcomes between the two groups",[327],"Laryngomalacia",[329,330,331,332,333],"laryngomalacia","aspiration","PPI","GERD","Pediatric","2026-08-02",{"date":336,"type":34},"2026-08-06",{"date":338,"type":34},"2026-04-28",{"date":340,"type":23},"2026-12-31",{"name":40,"class":41},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":17,"sex":18,"minAge":349,"maxAge":300,"enrollmentInfo":350,"targetDuration":4,"studyType":24,"phases":352,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100649249","3d-printed-vs-conventional-fixed-retainers-after-orthodontic-treatment-100649249","NCT07730476","3D-Printed vs Conventional Fixed Retainers After Orthodontic Treatment","Comparison Between Three-Dimensionally Printed Fixed Retainers Versus Conventional Multistranded Stainless Steel Fixed Retainers: Randomized Clinical Trial","Inclusion Criteria:\n\n* Age range 21-35 years old after finishing orthodontic treatment.\n* Presence of all maxillary and mandibular anterior teeth with normal shape and size.\n* Completion of orthodontic treatment with full fixed appliances.\n\nExclusion Criteria:\n\n* Patients with cleft lip and\u002For palate or any other craniofacial syndrome\n* Patients with compromised oral hygiene or periodontal disease\n* Patients who had orthognathic surgery\n* Lingual appliance treatments\n* Enamel hypoplasia, fluorosis, active caries, restorations, or fractures in the anterior teeth\n* Patients who had separate arch debondings with a difference of more than 2 months in-between jaws","21 Years",{"count":351,"type":23},36,[26],"This randomized clinical trial aims to compare the clinical performance of two types of three-dimensionally printed fixed retainers (Cobalt-Chromium and Titanium Grade 5) with the conventional multistranded stainless steel fixed retainer following orthodontic treatment. Thirty-six participants will be randomly allocated into three parallel groups with a 1:1:1 allocation ratio. The primary outcome is post-treatment stability assessed by Little's Irregularity Index and lower arch dimensions. Secondary outcomes include bond failure rate and periodontal parameters over a 12-month follow-up period.",[355,356],"Orthodontic Relapse","Malocclusion",[358,359,360,361,362,363,364,365],"Orthodontic retention","Fixed retainer","3D-printed retainer","Cobalt-Chromium","Titanium","Multistranded stainless steel retainer","Randomized clinical trial","Little's Irregularity Index","2026-07-30",{"date":368,"type":34},"2026-07-31",{"date":36,"type":23},{"date":371,"type":23},"2027-09-01",{"name":40,"class":41},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":299,"minAge":51,"maxAge":228,"enrollmentInfo":379,"targetDuration":4,"studyType":24,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":42},"100633361","temporary-uterine-tourniquet-application-versus-local-myometrial-epinephrine-injection-during-laparoscopic-myomectomy-100633361","NCT07525687","Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy","Inclusion Criteria:\n\n* Female patients aged 18-45 years.\n* Diagnosed with symptomatic uterine leiomyomas requiring laparoscopic myomectomy.\n* Presence of at least one myoma with a diameter ≥3 cm and ≤10 cm.\n* Patients with up to 3 myomas (to standardize surgical complexity).\n* Preoperative hemoglobin level ≥10 g\u002FdL.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with more than 3 myomas or any myoma larger than 10 cm.\n* Patients with suspected uterine malignancy (e.g., leiomyosarcoma).\n* Patients with known bleeding disorders or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with significant cardiovascular disease, uncontrolled hypertension, or arrhythmias (relative contraindications for epinephrine).\n* Patients with active pelvic infection.\n* Patients with previous extensive uterine surgery (e.g., multiple prior myomectomies or extensive uterine reconstruction) that may compromise uterine integrity.\n* Patients undergoing concurrent major gynecological procedures that might significantly affect blood loss (e.g., hysterectomy, extensive adhesiolysis).\n* Patients with known allergy to epinephrine.\n* Patients unwilling or unable to comply with follow-up protocols.",{"count":380,"type":23},74,[26],"While both local vasoconstrictors and tourniquet application are recognized methods for blood loss control, there is a paucity of head-to-head randomized controlled trials directly comparing these two distinct approaches in laparoscopic myomectomy. Existing data often compare these methods to no intervention or to other less common techniques. A direct comparison is essential to determine which method offers superior hemostasis with an acceptable safety profile in the laparoscopic setting. This study aims to address this gap in the literature.",[384],"Laparoscopic Myomectomy","2026-07-19",{"date":387,"type":34},"2026-07-21",{"date":389,"type":34},"2026-04-20",{"date":391,"type":23},"2027-01-20",{"name":40,"class":41},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":299,"minAge":51,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":24,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":42},"100633360","vacuum-sealing-drainage-vsd-in-promoting-wound-healing-and-reducing-complications-in-post-infected-obstetric-and-gynecological-surgical-sites-100633360","NCT07525674","Vacuum Sealing Drainage (VSD) in Promoting Wound Healing and Reducing Complications in Post-Infected Obstetric and Gynecological Surgical Sites","Inclusion Criteria:\n\n* Diagnosis of a surgical site infection (SSI) following an obstetric or gynecological surgical procedure (e.g., Cesarean section, hysterectomy, myomectomy, salpingo-oophorectomy).\n* Wound classification as superficial incisional SSI, deep incisional SSI, or organ\u002Fspace SSI (if accessible for VSD application).\n* Willingness and ability to provide informed consent.\n* Wound requiring secondary intention healing or delayed primary closure after debridement\n\nExclusion Criteria:\n\n* Patients with necrotic tissue.\n* Presence of exposed blood vessels, organs, or anastomotic sites where VSD is contraindicated.\n* Untreated coagulopathy or active bleeding diathesis.\n* Allergy to VSD components or dressing materials.\n* Patients with significant immunosuppression (e.g., uncontrolled HIV, organ transplant recipients on high-dose immunosuppressants).\n* Patients with malignant wounds.\n* Patients who decline participation.\n* Patients requiring immediate primary wound closure without debridement.\n* Patients with a known history of severe psychiatric illness affecting compliance.","70 Years",{"count":323,"type":23},[26],"This study aims to evaluate the efficacy of VSD in promoting wound healing and reducing complications, such as re-infection, prolonged hospitalization, and need for further surgical interventions, in obstetric and gynecological patients who have developed surgical site infections following their primary procedures. The investigators hypothesize that VSD will lead to faster wound healing, fewer complications, and improved patient outcomes compared to conventional wound care in this specific patient population.",[404],"Wound Heal",{"date":387,"type":34},{"date":389,"type":34},{"date":408,"type":23},"2027-04-20",{"name":40,"class":41},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":416,"maxAge":228,"enrollmentInfo":417,"targetDuration":4,"studyType":24,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100648226","postoperative-pain-after-using-a-minimally-invasive-reciprocating-single-file-system-in-mandibular-molars-with-symptomatic-irreversible-pulpitis-100648226","NCT07718607","Postoperative Pain After Using a Minimally Invasive Reciprocating Single-file System in Mandibular Molars With Symptomatic Irreversible Pulpitis","Inclusion Criteria:\n\n* Adult patients who have vital mandibular molar teeth with irreversible pulpitis without apical periodontitis.\n* Medically free patients.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Patients with para functional habits.\n* Teeth with non-vital pulps and periapical lesions.\n* The presence of swelling or a fistulous tract.\n* Any periodontal pockets with a depth more than 5 mm.\n* Previous endodontic fillings.\n* Patients with a history of any systemic diseases.\n* Severely curved canals and calcified ones.","19 Years",{"count":418,"type":23},56,[26],"The aim of the present study is to assess the incidence and severity of postoperative pain after root canal preparation of mandibular molars with symptomatic irreversible pulpitis using a minimally invasive reciprocating single-file system in comparison to Wave One Gold.",[422],"Root Canal Infection","2026-07-17",{"date":425,"type":34},"2026-07-22",{"date":368,"type":23},{"date":428,"type":23},"2026-10-31",{"name":40,"class":41},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":42},"100645642","clinical-and-radiographic-assessment-of-first-permanent-molars-with-cention-n-100645642","NCT07703176","Clinical and Radiographic Assessment of First Permanent Molars With Cention-N","Assessment of Clinical, Radiographic, and Oral Health-Related Quality of Life Following Restoration of First Permanent Molars With Cention-N: A 12-Month Split-Mouth Randomized Controlled Trial","Cention-N","Inclusion Criteria:\n\nClinical:\n\n1. Children aged 8-10 years.\n2. Children classified as ASA physical status I or II.\n3. Children demonstrate positive or definitely positive behavior (scores 3 or 4 on the Frankl Behavior Rating Scale).\n4. Children who are available for regular recall visits throughout the study period.\n5. Presence of bilateral carious lesions in permanent first molars, with a clear description of lesion depth whenever possible.\n6. Asymptomatic vital permanent first molars showing no clinical or radiographic signs of pathology.\n\nRadiographic:\n\n1. Normal lamina dura and periodontal ligament space.\n2. No apical radiolucency.\n\nExclusion Criteria:\n\nClinical:\n\n1. Children with behavioral difficulties or without signed parental consent.\n2. Children are classified as ASA physical status class III or higher.\n3. Teeth presenting clinical signs of pulpitis or necrosis (e.g., nocturnal pain, fistula, abscess, pulp exposure, or pathological mobility).\n\nRadiographic:\n\n1. Evidence of abnormal radiolucency involving the pulp chamber or root apex.\n2. Detection of furcal bone radiolucency or abnormal root resorption.","8 Years","10 Years",{"count":441,"type":23},100,[26],": Assessment of Clinical, Radiographic, and Oral Health-Related Quality of Life Following Restoration of First Permanent Molars with Cention N: A 12-Month Split-Mouth Randomized Controlled Trial\n\nIntroduction\n\nDental caries is one of the most common chronic diseases affecting children. First permanent molars (FPMs) are particularly susceptible to caries because of their early eruption and complex occlusal anatomy. Restorative treatment aims to preserve tooth function and prevent disease progression. Composite resin is widely used because of its esthetics and mechanical properties; however, polymerization shrinkage may compromise marginal integrity. Cention N is a newer alkasite restorative material that releases fluoride, calcium, and hydroxide ions, promoting remineralization and enhancing caries resistance. Since treatment success should include both clinical outcomes and patient-centered outcomes, oral health-related quality of life (OHRQoL) will also be assessed.\n\nAim\n\nTo compare the clinical and radiographic performance of Cention N and bioactive injectable resin composite in restoring first permanent molars over 12 months. A secondary objective is to evaluate changes in children's oral health-related quality of life.\n\nMaterials and Methods\n\nThis will be a split-mouth randomized controlled clinical trial involving 100 children aged 8-10 years.\n\nInclusion criteria:\n\nHealthy children (ASA I or II). Positive\u002Fdefinitely positive behavior (Frankl 3 or 4). Bilateral carious first permanent molars. Vital, asymptomatic teeth without radiographic pathology.\n\nExclusion criteria:\n\nLack of parental consent. ASA III or higher. Teeth with signs of irreversible pulp disease or radiographic pathology.\n\nEthical approval will be obtained from the Research Ethics Committee, Faculty of Dentistry, Minia University, and written informed consent will be obtained from parents.\n\nClinical Procedure\n\nFollowing clinical and radiographic examination, local anesthesia and rubber dam isolation will be performed. Caries will be removed conservatively, followed by acid etching and adhesive application.\n\nOne molar will be restored with bioactive injectable resin composite according to the manufacturer's instructions.\n\nThe contralateral molar will be restored with Cention N, mixed and placed according to the manufacturer's instructions, with optional light curing.\n\nAll restorations will be finished and polished using standardized procedures.\n\nOutcome Assessment\n\nPrimary outcome\n\nClinical and radiographic evaluation at 3, 6, and 12 months using the modified USPHS criteria, including:\n\nColor match Marginal adaptation Marginal discoloration Anatomic form Secondary caries Restoration integrity\n\nSecondary outcome Assessment of oral health-related quality of life using the Child Perceptions Questionnaire (CPQ8-10), which evaluates oral symptoms, functional limitations, emotional well-being, and social well-being.\n\nStatistical Analysis\n\nCollected data will be tabulated and analyzed using appropriate statistical methods to compare the performance of both restorative materials over the follow-up period.",[445],"Dental Caries",[447],"Cention N Clinical Trial","2026-07-13",{"date":450,"type":34},"2026-07-15",{"date":452,"type":34},"2026-03-09",{"date":454,"type":23},"2027-09-09",{"name":40,"class":41},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":42},"100645615","incidence-of-hypoxia-during-intravitreal-anti-vegf-vascular-endothelial-growth-factor-injections-for-retinopathy-of-prematurity-rop-under-topical-anesthesia-100645615","NCT07701759","Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia","Hyopxia During Anti-VEGF Injection","Inclusion criteria\n\n* Premature infants with treatment-requiring ROP.\n* Treatment with intravitreal ranibizumab.\n* Complete procedural monitoring records, including continuous pulse oximetry.\n* Availability of follow-up data after treatment. Exclusion criteria\n\nInfants were excluded if they had:\n\n* Incomplete procedural or follow-up data.\n* Major congenital anomalies affecting cardiorespiratory function.\n* Bronchopulmonary dysplasia.\n* Intraventricular hemorrhage.\n* Patent ductus arteriosus.\n* Respiratory distress syndrome requiring surfactant therapy.",{"count":380,"type":23},"Purpose:\n\nTo evaluate the incidence and severity of hypoxia and address a genuine evidence gap focusing on intraprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity (ROP), an area that has been only sparsely investigated in premature infants treated across multiple hospitals in the Al Qassim region of Saudi Arabia\n\nMethods:\n\nA retrospective multicenter observational study was conducted at Ophthalmology Department, Qassim University Medical City involving premature infants who underwent intravitreal Ranibizumab injection for treatment-requiring ROP between July 2020 and June 2026. Demographic, maternal, perinatal, ophthalmic, and treatment-related data were collected registered and analyzed. Continuous pulse oximetry monitoring was recorded during bedside neonatal intensive care unit (NICU) procedures. Hypoxia was classified as mild (oxygen saturation 85-89%), moderate (80-84%), or severe (\\\u003C80%).",[466],"Retinopathy of Prematurity","2026-07-08",{"date":469,"type":34},"2026-07-14",{"date":471,"type":34},"2025-10-01",{"date":473,"type":23},"2026-10-01",{"name":40,"class":41},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":158,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":42},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635","NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.",{"count":441,"type":23},[26],"Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[487,488,489,490,491,492,493],"Pancreas Cancer","Pancreas Neoplasm","Pancreatic Fistula","Pancreas Adenocarcinoma","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer","2026-06-27",{"date":496,"type":34},"2026-07-01",{"date":498,"type":34},"2025-06-20",{"date":500,"type":23},"2026-10-20",{"name":40,"class":41},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":158,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":42},"100573225","external-pancreatic-stent-in-pancreaticojejunostomy-100573225","NCT06743516","External Pancreatic Stent in Pancreaticojejunostomy","The Impact of External Pancreatic Drainage During Pancreaticojejunostomy Following Pancreaticoduodenectomy in Cases of Soft Pancreas","Inclusion Criteria:\n\n* Patients undergoing pancreaticoduodenectomy (Whipple procedure) for various indications (e.g., pancreatic cancer, ampullary cancer, etc.).\n* Patients with a confirmed soft pancreas texture, as determined intraoperatively by the surgeon.\n\nExclusion Criteria:\n\n* Patients with a hard or fibrotic pancreas, as determined intraoperatively by the surgeon.\n* Patients with severe uncontrolled comorbidities (e.g., uncontrolled diabetes, severe cardiovascular disease, renal failure).\n* Pregnancy or lactation.",{"count":441,"type":23},[26],"Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend pancreatic stent in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula and to investigate its long term clinical outcomes.",[489],{"date":514,"type":34},"2026-06-30",{"date":516,"type":34},"2025-01-01",{"date":114,"type":23},{"name":40,"class":41},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":399,"enrollmentInfo":526,"targetDuration":4,"studyType":24,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":539},"100631429","ultrasound-guided-infratemporal-sphenopalatine-ganglion-supravoltage-versus-standard-voltage-pulsed-radiofrequency-for-pain-alleviation-in-chronic-refractory-migraine-100631429","NCT07500558","Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine.","Ultrasound Guided Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine. Randomized Double Blind Study","Inclusion Criteria:\n\n* Diagnosis of chronic migraine according to International Classification of Headache Disorders criteria (≥15 headache days\u002Fmonth for \\>3 months, including ≥8 migraine days\u002Fmonth) documented by Completion of 4-week prospective baseline headache diary immediately preceding randomization\n\n  * Failure of ≥2 classes of preventive pharmacological migraine medications (e.g., beta-blockers, antiepileptics, antidepressants...) to get clinically meaningful response ( defined as ≥50% reduction in monthly migraine days), at standard therapeutic doses (Beta-blockers (e.g., propranolol ≥160 mg\u002Fday, metoprolol ≥100 mg\u002Fday, Antiepileptics (e.g., topiramate ≥100 mg\u002Fday, valproate ≥500 mg\u002Fday, Tricyclic antidepressants (e.g., amitriptyline ≥50 mg\u002Fday, SNRIs (e.g., venlafaxine ≥150 mg\u002Fday ) for at least 8 weeks or ≥12 weeks in case of CGRP ).\n  * Stable preventive migraine therapy for at least 4 weeks prior to enrollment.\n  * MIDAS score ≥11 indicating moderate to severe disability.\n  * Ability and willingness to maintain a daily headache diary throughout the study period.\n  * Ability to provide written informed consent. Positive response (≥50% pain reduction within 30-60 minutes) to diagnostic INFRATEMPORAL sphenopalatine ganglion block using 2% lidocaine (2 mL) infrazygomatic approach\n\nExclusion Criteria:\n\n* Medication Overuse Headache per ICHD-3: Simple analgesics (acetaminophen, NSAIDs, non-opioid analgesics) used on ≥15 days per month for \\>3 months, OR Triptans, ergot derivatives, opioids, or combination analgesics used on ≥10 days per month for \\>3 months.\n* Any secondary headache disorder ( cluster headache, hemiplegic migraine, migraine with brainstem aura (distinct pathophysiology); chronic tension-type headache \\>10 days\u002Fmonth.\n* Any prior SPG block, PRF, radiofrequency thermocoagulation, chemical neurolysis, or neurostimulation of SPG\u002Ftrigeminal system within 6 month.\n* No prior occipital or supra-orbital nerve radiofrequency, cryotherapy, or chemical neurolysis within 3 months\n* Use of botulinum toxin (Botox) within 3 months or CGRP monoclonal antibodies within 3 months prior to enrollment.\n* Active psychosis, bipolar disorder (current manic\u002Fdepressive episode), severe depression with suicidal ideation, dementia, or substance use disorder (DSM-5 criteria) within 12 months; PHQ-9 ≥20 or cognitive impairment affecting reporting reliability.\n* Cardiac pacemaker, ICD, neurostimulator, or cochlear implant; or ECT.\n* Chronic uncontroled hypertension ; history of stroke, intracranial aneurysm, or high risk for cardiovascular events.\n* Pregnancy or lactation, Initiation, discontinuation, or modification of hormonal contraceptive therapy within 3 months prior to enrollment.\n\nCoagulopathy (platelets \\\u003C100,000 or INR \\>1.5) or ongoing anticoagulation not safely withheld.\n\n-Patient refusal.",{"count":441,"type":23},[26],"* PRF performed on the sphenopalatine ganglion level under ultrasound guidance.\n* Standard voltage PRF parameters: 45 V, 5 Hz frequency, 5 ms pulse width, 360 seconds duration, electrode temperature ≤42°C.\n* Supravoltage PRF parameters: Higher voltage than standard (e.g., 60-70 V), with same frequency, pulse width, and duration, maintaining temperature ≤42°C to avoid nerve damage.",[530],"Chronic Migraine, Headache","2026-06-13",{"date":533,"type":34},"2026-06-16",{"date":535,"type":34},"2026-03-31",{"date":537,"type":23},"2027-04-02",{"name":40,"class":41},2,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":299,"minAge":51,"maxAge":228,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":4},"100639171","impact-of-vertical-vs-transverse-closure-on-outcomes-of-laparoscopic-correction-of-isthmocele-100639171","NCT07625852","Impact of Vertical vs. Transverse Closure on Outcomes of Laparoscopic Correction of Isthmocele","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosis of symptomatic isthmocele confirmed by transvaginal ultrasound (myometrial thickness at the defect \\\u003C 2.5 mm).\n* History of at least one prior cesarean section.\n* Symptoms attributable to isthmocele (e.g., abnormal uterine bleeding, pelvic pain, dysmenorrhea, secondary infertility).\n* Desire for surgical correction of isthmocele.\n* Ability to understand and provide informed consent\n\nExclusion Criteria:\n\n* Asymptomatic isthmocele.\n* Active pelvic infection or malignancy.\n* Significant medical comorbidities contraindicating laparoscopic surgery.\n* Coagulopathy.\n* Known uterine anomalies (e.g., bicornuate uterus).\n* Pregnancy at the time of recruitment.\n* Inability to comply with follow-up protocol.",{"count":547,"type":23},72,[26],"Laparoscopic repair of Isthmocele aims to restore the anatomical integrity and physiological function of the lower uterine segment.\n\n* Vertical Closure: This technique involves closing the defect along the longitudinal axis of the uterus. Proponents suggest it may be more anatomically aligned with the muscle fibers of the lower uterine segment, potentially leading to stronger scar formation and reduced tension.\n* Transverse Closure: This technique involves closing the defect perpendicular to the long axis of the uterus. This approach is more commonly used during primary cesarean sections.\n\nArguments for transverse closure in isthmocele repair include familiarity for surgeons and potentially less shortening of the lower uterine segment.\n\nHowever, the actual impact of these different closure methods on long-term outcomes such as defect recurrence, scar integrity, and fertility, remains largely unexplored in a randomized controlled trial setting.",[551],"Isthmocele","2026-05-29",{"date":554,"type":34},"2026-06-04",{"date":556,"type":23},"2026-06-01",{"date":558,"type":23},"2027-06-01",{"name":40,"class":41},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":399,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":42},"100638194","effect-of-silicon-oil-on-retinal-electrical-functions-using-multifocal-electroretinogram-100638194","NCT07609628","Effect of Silicon Oil on Retinal Electrical Functions Using Multifocal Electroretinogram","Effect of Silicon Oil on Retinal Electrical Functions in Patients With Rhegmatogenous Retinal Detatchment Using Multifocal Electroretinogram .","SO\u002FRRD\u002FmfERG","Inclusion Criteria:\n\n\\- Patients with primary rhegmatogenous retinal detachment\n\nExclusion Criteria:\n\n* Patients with history of previous intraocular surgery.\n* Patients with combined traction-rhegmatogenous retinal detachment\n* Patients with ocular disease as glaucoma ,degenerative myopia,age related macular degeneration\n* Patients with poor fixation.\n* Uncooperative patients.\n* Patients with retinopathy.\n* emulsified SO or complicated SO removal were excluded from this study",{"count":569,"type":23},50,[26],"Retinal detachment is one of the leading causes for permanent vision loss.Incidence of Rheugmatogenous Retinal Detachment (RRD) about 10.5 people per 100,000 population pars plana vitrectomy is the most popular and effective surgical options.\n\nTamponade agents as silicone oils are used to restore intraocular volume and apply surface tension to the detached retinal surface Silicone oil (SO) is a liquid containing polymerized siloxane with organic side chains. It has a high thermal stability, is hydrophobic, and chemically inert. The use of silicone oils as intraocular tamponades dates from 1962.",[573],"Rhegmatogenous Retinal Detachment","2026-05-21",{"date":576,"type":34},"2026-05-27",{"date":578,"type":34},"2026-02-01",{"date":36,"type":23},{"name":40,"class":41},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":589,"enrollmentInfo":590,"targetDuration":592,"studyType":54,"phases":4,"briefSummary":593,"conditions":594,"keywords":598,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":42},"100604066","anastomotic-leakage-after-colorectal-surgery-100604066","NCT07144683","Anastomotic Leakage After Colorectal Surgery.","Risk Factors for Anastomotic Leakage After Colorectal Surgery.","AL","Inclusion Criteria:\n\n* Aged ≥18 years\n* Undergoing elective or emergency colorectal resection with primary anastomosis (e.g., ileocolic, colocolic, colorectal, coloanal)\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Colorectal resection without anastomosis (e.g., end stoma)\n* Inflammatory bowel disease (Crohn's, ulcerative colitis)\n* History of previous colorectal surgery involving anastomosis\n* Pregnancy\n* Unable to provide informed consent or comply with follow-up","80 Years",{"count":591,"type":23},430,"1 Year","Anastomotic leakage (AL) is a severe complication after colorectal surgery, with incidence rates of 2-30%. This prospective, single-center observational cohort study aims to identify and quantify independent risk factors for AL, determine its incidence and impact on outcomes, and develop a predictive model. Approximately 430 patients undergoing colorectal resection with anastomosis will be enrolled from August 2025 to August 2026. Risk factors will be assessed preoperatively, intraoperatively, and postoperatively. AL will be defined and graded per the International Study Group of Rectal Cancer (ISGRC) criteria.",[595,596,597],"Anastomotic Leak","Colorectal Cancer","Diverticulitis",[599,600,140,601,602],"Anastomotic leakage","Colorectal surgery","Postoperative complications","Predictive model","2026-05-17",{"date":605,"type":34},"2026-05-19",{"date":607,"type":34},"2025-08-25",{"date":609,"type":23},"2026-09-25",{"name":40,"class":41},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":626,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":4},"100637480","effect-of-a-herbal-intracanal-medication-on-postoperative-pain-and-flare-up-incidence-in-non-surgical-root-canal-retreatment-100637480","NCT07578311","Effect of a Herbal Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment","Effect Of Phytotherapeutics As Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment. (Randomized Clinical Trial)","Inclusion Criteria:\n\n* Failed previously performed endodontic treatment of single-rooted teeth.\n* Presence of a periapical lesion ranging from 1 mm to 2 mm in diameter.\n* Teeth with complete root formation.\n* Teeth without evidence of external or internal root resorption.\n\nExclusion Criteria:\n\n* Pregnant females.\n* Patients with uncontrolled systemic diseases.\n* Patients currently under antibiotic or analgesic administration.\n* Patients presenting with facial swelling.\n* Teeth not indicated for endodontic retreatment (e.g., poor oral hygiene, mobile teeth, or recessed teeth).",{"count":619,"type":23},40,[26],"The primary objective of this randomized clinical trial is to evaluate and compare the effectiveness of two natural, herbal-based intracanal medications-Propolis and Green Tea Polyphenolics (EGCG)-against the conventional Calcium Hydroxide in reducing postoperative pain and the incidence of flare-ups during non-surgical root canal retreatment.\n\nPostoperative pain is a common complication in endodontics, particularly in retreatment cases where complex bacterial environments and procedural challenges increase the risk of discomfort and acute flare-ups. While Calcium Hydroxide is the traditional gold standard due to its antimicrobial properties, natural phytotherapeutics like Propolis and Green Tea are being investigated for their potent anti-inflammatory, antioxidant, and antibacterial benefits, which may offer superior biocompatibility and symptomatic relief.\n\nForty patients requiring endodontic retreatment of single-rooted teeth will be randomly assigned to one of three groups:\n\nGroup I (Control): Receives Calcium Hydroxide paste.\n\nGroup II: Receives Propolis-based medication.\n\nGroup III: Receives Green Tea Polyphenolic-based medication.\n\nThe study follows a two-visit protocol. During the first visit, the previous root canal filling is removed, the canal is cleaned and shaped, and the assigned medication is placed. Postoperative pain will be assessed using a Visual Analog Scale (VAS) at 6, 12, 24, 48, 72 hours, and 7 days. Flare-up incidence (sudden severe pain or swelling) will also be monitored. In the second visit, the medication is removed, and the canal is permanently sealed using a bioceramic sealer and gutta-percha. The results will help determine if these herbal alternatives can provide a more comfortable treatment experience for patients undergoing root canal retreatment.",[623,624,625],"Postoperative Pain","Flare Up, Symptom","Flare up",[627,628,629,630,631,632],"postoperative pain","flare up","intra-canal medication","calcium hydroxide","propolis","Green Tea Polyphenolics","2026-05-05",{"date":635,"type":34},"2026-05-11",{"date":637,"type":23},"2026-07",{"date":639,"type":23},"2027-02",{"name":40,"class":41},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":158,"enrollmentInfo":648,"targetDuration":4,"studyType":24,"phases":650,"briefSummary":651,"conditions":652,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":42},"100573076","early-phase-1-pre-operative-intra-nasal-dexmedetomidine-or-insulin-for-prevention-of-early-post-operative-cognitive-dysfunction-in-patients-undergoing-elective-coronary-artery-bypass-graft-100573076","NCT06741566","Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.","Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft. A Comparative Randomized Bi-centric Study","Inclusion Criteria:\n\n* Adult population, 60 years or above, both sex, candidate for elective on pump coronary revascularization\n\nExclusion Criteria:\n\n* patient refusal\n* combined reperfusion and valve replacement operations.\n* Emergency or redo CABG.\n* preoperative MMSE score less than 20\n* preoperative cardiomyopathy (ejection fraction \\\u003C40%).\n* previous history of cerebrovascular stroke or carotid endarterectomy, dementia, language, hearing or visual impairment precluding accurate neurocognitive assessment.\n* history of heparin resistance.\n* chronic use of hypnotics (\\>3 times weekly for \\>4 weeks), mood stabilizing drugs (lithium, Na valoprate, anticonvulsants) or melatonin.\n* pre-operative pacing.\n* recent nasal surgery (\\\u003C3 months), prior maxillofacial trauma with nasal deformity, nasal polyposis or severe allergic rhinitis.\n* severe obstructive sleep apnea (apnea hypopnea index \\>30), central sleep apnea or obesity-hypoventilation syndrome, and planned postoperative non-invasive ventilation.\n* Chronic acholic population Alcohol Use Disorders Identification Test (AUDIT) score ≥8 for men or ≥7 for women",{"count":649,"type":23},150,[304],"On pump coronary revascularization is a very common leading cause for post-operative cognitive dysfunction regarding patient age grouping and diffuse systemic inflammatory response induced by bypass machine . Many factors are incriminated as pre-operative sleep disturbance, previous history of neurocognitive dysfunction. The accumulating evidence refers to an incidence between 20-40% with majority among geriatric population. The primary pathology is still elusive and many trials are under evaluation. Neuro-inflammation, hypo perfusion, fat emboli and reperfusion injury are among the most postulative aetiologias. The corner stone in the pathology of postoperative cognitive dysfunction is abnormal sleep rhythm. Intra-nasal insulin can provide neuroprotection via providing insulin growth factor and obtund neuronal apoptosis , while dexmedetomidine can antagonize neural-degeneration via regulation of systematic inflammatory cytokines including interleukin 1β, tumor necrosis factor-α, and NF-κB, inhibiting the expressions of Toll-like receptor , and through α2 adrenoceptor-mediated anti-inflammatory pathways",[653],"Post Operative Cognitive Dysfunction",{"date":655,"type":34},"2026-05-04",{"date":657,"type":34},"2024-12-27",{"date":659,"type":23},"2026-05-15",{"name":40,"class":41},""]